16th June 2016

TrakCel completes rights issue and appoints Jim Langford as US CEO

TrakCel, a provider of supply chain technology to aid in the processing of regenerative therapies, has successfully completed a rights issue leading to significant new hires and appointed a new US Chief Executive Officer with regional responsibility for the company’s fast growing US and Canadian activities.

The successful completion of the company’s rights issue follows a series of significant new contract wins in the USA and allows the business to further enhance its technology platform and progress plans to expand its US and Canadian presence.

Over 80% of the Rights Issue was taken up by virtue of subscription rights, with the remainder allotted to general investor demand without those rights. Broad based demand for the issue was received, reflecting the company’s diverse investor base and continued buoyancy in its core Cell, Gene and Immunotherapy markets.

Keren Winmill, Chairman, TrakCel said: “We are extremely pleased with the outcome of the Rights Issue. This success is a welcome vote of confidence from our existing shareholders as well as new incoming investors in support of our long-term strategic vision in the Cell, Gene and Immunotherapy markets.”

TrakCel also today announced the appointment of Jim Langford as chief executive of the company’s rapidly evolving US operations. Mr. Langford has been a leader in the biopharmaceutical clinical development industry for over 25 years, having founded and managed several companies to leadership positions in the industry including DataLabs, Inc. an electronic data management company, where he served as President and CEO from 2001 until leading the sale of the business to Clinphone, PLC, in 2006, which was subsequently sold to PAREXEL International.

Prior to founding DataLabs, Jim created and lead a Contract Research Organization, The PHOENIX, where they successfully managed over 300 clinical studies in all therapeutic areas for the pharmaceutical, biotechnology and medical device industries, over a 16 year period. Most recently, Mr. Langford was a principal at White Star Consulting, where he led their practice in the cell therapy industry.

Keren Winmill, Chairman, TrakCel also said: “We are thrilled to have someone of Jim’s experience and background to guide TrakCel in meeting our aggressive ambitions for US growth and achieving our goal of delivering a world class technology platform.”

The announcement is part of a series of strategic developments within the business as it builds upon its Clinical and commercial success across the globe.